Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy

Marta Massanella1,*, Sara Gianella1,*, Rachel Schrier1, Jennifer M. Dan1,2, Josué Pérez-Santiago1, Michelli F. Oliveira1, Douglas D Richman1,2, Susan J Little1, Constance A Benson1, Eric S Daar4, Michael P. Dubé5, Richard H Haubrich1, Davey M Smith1,3 & Sheldon R. Morris1

We investigated the associations between methamphetamine (meth) use, immune function, and the dynamics of HIV and cytomegalovirus (CMV) in the blood and genital tract of HIV-infected ART-suppressed subjects. Self-reported meth use was associated with increased CD4+ and CD8+ T-cell proliferation (Ki67+, p<0.005), CD4+ T-cell activation (CD45RA–CD38+, p=0.005) and exhaustion (PD-1+, p=0.0004) in blood, compared to non-meth users. Meth use was also associated with a trend towards higher blood HIV DNA levels (p=0.09) and more frequent shedding of CMV in seminal plasma (p=0.002). To explore possible mechanisms, we compared ex vivo spontaneous and antigen-specific proliferation in PBMC collected from subjects with and without positive meth detection in urine (Utox+ vs. Utox-). Despite higher levels of spontaneous proliferation, lymphocytes from Utox+ meth users had a significantly lower proliferative capacity after stimulation with a number of pathogens (CMV, candida, mycobacterium, toxoplasma, HIV, p<0.04 in all cases), compared to Utox-participants. Our findings suggest that meth users have greater proliferation and exhaustion of the immune system. Meth use is also associated with a loss of control of CMV replication, which could be related to loss of immune response to pathogens. Future studies should consider meth use as a potential modulator of T-cell responses.

Methamphetamine (meth) is a widely used recreational drug in North America1–3, and its use is highly prevalent among HIV-infected men who have sex with men (MSM)4. Meth can be self-administered intravenously, by nasal inhalation, smoking, anal insertion, or oral consumption in doses ranging from 250 to 500 mg for occasional users to as much as 1 gram by chronic addicts. Users also tend to consume meth in ‘binges’, and, as the drug has a half-life of 12 hours, this can lead to extremely high levels in blood5,6. Despite substantial evidence of the effects of meth use on the central nervous system and its association with neurocognitive impairment, the effects of meth on the immune system have not been extensively described. In murine models, meth has been described as an immunosuppressive agent by inhibiting antigen presentation, impairing phagocytosis and reducing the microbicidal capacity of macrophages7,8. Furthermore, meth exposure of primary human T cells in vitro induces in mitochondrial oxidative damage resulting in cellular dysfunction9.
In HIV-infected individuals, meth use is associated with delayed viral suppression after the initiation of antiretroviral therapy (ART), higher levels of blood HIV RNA, increased frequency of drug resistance mutations, and accelerated progression to AIDS. Moreover, meth use is associated with significantly increased risk of other infectious diseases, HIV transmission, and mortality related to suicide and drug overdose. It is unclear if the associations between meth use and HIV disease progression and transmission are purely a consequence of reduced ART adherence, poor nutrition, and increased risk behaviors associated with meth consumption, or if there is a biological mechanism underlying these associations.

In vitro, meth is associated with increased cellular HIV transcription, immune activation and increased expression of the surface HIV co-receptor CCR5. Since activated T-cells undergo extensive cell division and differentiation, and the CCR5 co-receptor is an important co-factor in modulating cellular infection with HIV, we hypothesized that all these mechanisms might enhance HIV infection and contribute to maintaining the HIV reservoir size. Despite these effects of meth in vitro, little is known about the outcome of meth in vivo on T lymphocytes and macrophages and how it may further compromise immune function in the setting of HIV infection.

Here, we investigated a cohort of 50 chronically HIV-infected MSM virologically suppressed on long-term ART who were well characterized in terms of: ART use, meth use, other drug use, and disease state to determine the relationships between meth use, levels of immune activation and proliferation, levels of CCR5 expression on T cells and macrophages, and the size and transcriptional activity of the viral HIV reservoir. We also evaluated the effect of meth on the function of T-cells by measuring ex vivo proliferation capacity of PBMCs from subjects with meth present in their urine (urine toxicology positive) compared to meth negative controls after stimulation with antigens from various pathogens.

**Results**

**In vivo results from the California Collaborative Treatment Group (CCTG) samples.** Baseline characteristics CCTG Cohort participant. Of 50 HIV-infected MSM virologically suppressed on ART included in this study, 16 individuals reported regular meth use over the 12 months of follow-up. Among meth group, meth use was reported in 40% [IQR:21–79%] of all evaluated monthly surveys. Eleven individuals reported consumption of meth in the month immediately preceding sample collection. Compared to non-users, meth users more frequently reported the use of other recreational drugs such as marijuana, cocaine and other club drugs (p < 0.02 in all cases). Group characteristics are summarized in Table 1. The demographic and clinical parameters were mostly balanced between both groups; however, meth users were more commonly on regimens containing PI than the control group (p = 0.02). The majority (88%) of participants self-reported levels of ART adherence >90% during the preceding month with no difference between meth groups. The proportion of meth users with cytomegalovirus (CMV) shedding in seminal plasma was higher than in the non-meth user group (p = 0.002, Table 1). Although only 4 participants had HIV shedding in the genital tract in this cohort, there was a trend towards a higher frequency of genital HIV shedding in meth users (p = 0.09, Table 1). No difference was observed for Epstein-Barr virus (EBV) shedding. No differences were found in any sexually transmitted infections (STI) (Including Gonorrhea, Chlamydia, Syphilis, trichomonas, mycoplasma) between groups.

**Analysis of T-cell maturation subsets.** Due to the increased proportion of genital tract CMV-shedders in the meth use group and the described association between CMV-shedding and the enrichment of transitional memory (T_{tm}) and effector memory (T_{em}) in CD4 T-cell compartment, we analyzed the frequencies and absolute counts of CD8 and CD4 T-cell subsets (naive [T_n], central memory [T_cm], T_tm and T_em). There was no difference in the distribution (frequencies and absolute counts) of CD8 and CD4 T-cell subsets between meth and non-meth users (Supplementary Fig. 1). There was, however, a weak trend towards increased frequencies and absolute counts of circulating T_{tm} subset in CD4 T cells in the meth user group but this did not reach statistical significance (p < 0.1 in both cases).

**Analysis of T-cell activation.** Increased activation of CD4 and CD8 T cells, especially CD38 expression, is a hallmark of HIV infection that is associated with both progression to AIDS and response to ART in treated individuals. As naive T cells express CD38 without activation, we analyzed activation reflected by co-expression of CD38 and HLA-DR or the expression of these markers singularly in memory lymphocytes (CD45RA-). There were no differences in CD8 T-cell immune activation between groups, as measured by the frequency of CD45RA CD38 or HLA-DR/CD38 (Fig. 1A), but there was a trend towards higher levels of CD45RA HLA-DR in the non meth users compared to the users (p = 0.08, Fig. 1A). In contrast, immune activation in CD4 T cells was significantly higher in the meth user group compared to non-users, as measured by the frequency of CD45RA CD38 (p = 0.005, Fig. 1B). While CD4 T cells of meth users expressed higher levels of HLA-DR CD38 and CD45RA- HLA-DR, this difference was not significant (p = 0.12 and p = 0.11 respectively, Fig. 1B).

Since genital CMV-shedding has been associated with increased immune activation, we stratified both meth and control groups by seminal CMV-shedding status. In this sub-analysis, we observed that CD45RA CD38 in CD4 T cells was significantly increased in both meth user groups (i.e. meth+/non-CMV-shedders and meth+/-CMV-shedders) compared to controls (Supplementary Fig. 2).
However, this analysis was limited by the small sample size and deserves further investigation using a larger cohort of individuals.

Since treatment of macrophages with meth in vitro reportedly induces up-regulation of CCR5 expression and increases frequency of infection with HIV21, we explored the in vivo effect of meth-use on this marker on T-cells. Despite the observed in vitro effects, we did not observe any difference in CCR5 expression between meth use groups in either CD4+ or CD8+ T cells (Fig. 1C). We also evaluated the percentage and mean fluorescence intensity (MFI) of CCR5 expression on monocytes, and similar to T cells, we did not find any differences between groups in the expression of CCR5 on monocytes (Table 2).

The levels of sCD14 and sCD163, soluble markers of monocyte activation, also were not statistically different between groups (Table 2). Overall, these results suggest that a history of meth use is not associated with a sustained level of monocyte activation.

Analysis of T-cell proliferation. To investigate the levels of ongoing proliferation in total and T lymphocyte subsets we quantified the expression of Ki67, a nuclear antigen found in cycling cells. Total CD8+ T cells of reported meth users showed significantly higher percentages of Ki67 expression compared to non-users ($p = 0.002$, Fig. 2A). We also examined Ki67 expression among the different CD8+ T-cell maturation subsets. The proportion of proliferating CD8+ T_{em}, T_{im} and T_{em} cells were significantly

### Table 1. Participant characteristics.

|                        | Meth $^1$ n = 16 | Control n = 34 | P-value$^2$ |
|------------------------|------------------|----------------|-------------|
| Age (years), median [IQR] | 45 [36–49]       | 48 [40–54]     | 0.11        |
| Race/Ethnicity, n(%)    |                  |                |             |
| Caucasian              | 7(44)            | 14 (41)        | 1.00        |
| Latino                 | 4 (25)           | 13 (38)        | 0.052       |
| African American       | 4 (25)           | 6 (18)         | 0.72        |
| Other                  | 1 (6)            | 1 (3)          | 0.54        |
| Time on ART (years), median [IQR] | 4.4 [2.2–5.9] | 3.4 [1.7–5.7] | 0.51        |
| Nadir CD4+ T cell counts (cell/μl), median [IQR] | 204 [120–300] | 216 [60–386] | 0.94        |
| CD4+ T-cell counts (cell/μl), median [IQR] | 577 [485–835] | 652 [548–714] | 0.57        |
| CD4% median [IQR]      | 31 [25–36]       | 34 [28–37]     | 0.56        |
| CD8+ T-cell counts (cell/μl), median [IQR] | 852 [571–1113] | 820 [507–939] | 0.27        |
| CD8% median [IQR]      | 42 [38–52]       | 38 [31–46]     | 0.08        |
| Ratio CD4/CD8, median [IQR] | 0.72 [0.49–1.0] | 0.83 [0.66–1.2] | 0.13        |
| Antiretroviral treatment, n(%) |            |                |             |
| PI-based               | 13 (87)          | 17 (50)        | 0.02        |
| NNRTI-based            | 4 (27)           | 16 (47)        | 0.22        |
| Raltegravir containing regimen | 1 (7)           | 7 (21)         | 0.41        |
| Recreational drug use$^1$, n (%) |            |                |             |
| % of Positive surveys for Meth, median [IQR] | 40 [21–79] | NA             | <0.01       |
| Marijuana$^1$          | 11 (69)          | 9 (26)         | <0.01       |
| Cocaine$^1$           | 8 (50)           | 3 (9)          | <0.01       |
| Other Club Drug $^{1,3}$ | 8 (50)          | 5 (15)         | 0.01        |
| Alcohol$^{1,3}$        | 5 (31)           | 7 (21)         | 0.50        |
| Virus Shedding in semen, n (%) |            |                |             |
| HIV                    | 3 (19)           | 1 (3)          | 0.09        |
| CMV                    | 12 (75)          | 9 (26)         | <0.01       |
| EBV                    | 4 (25)           | 8 (24)         | 1.00        |
| Any other STI$^4$, n (%) | 2 (12.5)        | 3 (8.8)        | 0.64        |

$^1$Drug-users reported consumption of the specified drug at least in one survey over the period of the study. $^2$Other club drugs: Ecstasy, GHB, Amyl nitrates, ketamine. $^3$or more alcoholic drinks on a single occasion >5 times/month. $^4$STI: sexually transmitted infections, including Gonorrhea, Chlamydia, Syphilis, Trichomonas, mycoplasma. $^5$Mann-Whitney U test.
Figure 1. Effect of meth-use on immune activation and CCR5 expression on HIV ART-suppressed individuals. Immune activation markers and CCR5 expression in CD4 and CD8 T cells were assessed by flow cytometry using frozen PBMCs from the CCTG592 cohort. Comparison of CD8+ (Panel A) and CD4+ (Panel B) activation markers (measured as frequencies of CD45RA–CD38+, HLA-DR+CD38+ and CD45RA–HLA-DR+) and frequencies of CCR5 expression in total CD8+ and CD4+ T cells (Panel C) are plotted for meth-users (orange squares, n = 16) and control group (blue circles, n = 34). Individual and median values are shown. Two-sided p-values (Mann Whitney U test) are indicated.

|                      | Meth n = 16 | Control n = 34 | P-value² |
|----------------------|-------------|----------------|----------|
| MFI⁺ of CCR5⁺CD14⁺, median [IQR] | 2149 [1706–2912] | 2294 [1730–2941] | 0.89     |
| sCD14, ng/mL, median [IQR]      | 800 [723.6–1056] | 766.8 [586.9–888.9] | 0.21     |
| sCD163, ng/mL, median [IQR]     | 719.4 [516.2–1057] | 724.0 [581.8–861.8] | 0.86     |

Table 2. Monocyte activation. ¹Drug-users reported consumption of the specified drug at least in one survey over the period of the study. ²Mann Whitney U test. ³MFI: mean fluorescence intensity.
higher in meth users compared to non-users \((p = 0.03, p = 0.05\) and \(p = 0.004\), respectively, Fig. 2A) and the proportion of cycling naïve CD8\(^{+}\) T cells tended to be higher in the meth group \((p = 0.09)\). Similarly, total CD4\(^{+}\) T cells showed higher frequencies of Ki67\(^{+}\) cells in meth user group \((p = 0.005\), Fig. 2B). Among subsets, the meth users presented significantly higher levels of proliferating naïve CD4\(^{+}\) T-cells \((p = 0.02)\), while the other subsets (Tcm, Ttm and Tem) tended to have higher frequencies of Ki67\(^{+}\), but these differences did not reach statistical significance \((p = 0.07, p = 0.08\) and \(p = 0.06\), respectively, Fig. 2B).

Since the presence of genital tract CMV shedding has been associated with higher levels of CD4\(^{+}\) and CD8\(^{+}\) T-cell proliferation\(^{27}\) and meth users had a higher frequency of CMV-shedding than non-meth users, we performed a multivariate analysis adjusting for CMV shedding. In this analysis, meth use remained independently associated with CD4\(^{+}\) and CD8\(^{+}\) T-cell proliferation \((p < 0.05\) in both cases).

**Immune exhaustion.** As persistent lymphocyte proliferation can lead to cellular exhaustion, we examined the levels of PD-1, considered a marker of lymphocyte exhaustion. We did not find any difference between meth users and non-users in the frequency of PD-1\(^{+}\) total CD8\(^{+}\) T-cells or any of the CD8\(^{+}\) T-cell subsets \((p = 0.09\) in all cases). However, significantly higher frequencies of PD-1\(^{+}\) expression were detected in Tcm, Ttm and Tem among meth users \((p < 0.002\) in all cases). In a multivariate analysis, levels of CD4\(^{+}\) T-cell exhaustion remained independently associated with meth use after adjusting for the presence of CMV \((p = 0.004)\).

**Analysis of HIV DNA.** Increased inflammation and CD4\(^{+}\) T-cell proliferation have been associated with maintenance of the HIV cellular reservoir during suppressive ART\(^{32}\). Therefore, we investigated the effect of meth use on the levels of HIV DNA and cell-associated HIV RNA. A trend towards higher levels of total HIV DNA was found in the meth user group \((p = 0.09\), Fig. 4A) as well as a trend for increased levels of 2-LTR circles \((p = 0.08, p = 0.003\) and \(p = 0.004\) for cell-associated HIV RNA (unspliced [gag] and multiply spliced [tat/rev], Fig. 4B) or transcriptional activity (estimated as the cellular HIV RNA/HIV DNA ratio, data not shown) between meth user and non-user groups. Since genital tract CMV-shedding has also been associated with higher total HIV DNA levels\(^{31}\), we performed a multivariate analysis to adjust for this parameter. After this adjustment for CMV shedding, the increased levels of HIV DNA observed among meth users was no longer significant \((p = 0.38)\), suggesting that CMV shedding has a stronger effect on HIV DNA levels than a history of meth use.
Figure 3. Effect of meth-use on T-cell proliferation in HIV-infected ART-suppressed individuals. T-cell exhaustion (PD-1+) was assessed by flow cytometry using frozen PBMCs from the CCTG592 cohort. Exhaustion levels of CD8+ (Panel A) and CD4+ (Panel B) of total or T-cell subsets (Tn, Tcm, Tem and Ttd) are plotted from meth-users (orange squares, n = 16) and control group (blue circles, n = 34). T-cell subsets in CD8+ and CD4+ T cells were defined as: Tn, CD45RA+CD27+CD28+; Tcm, CD45RA−CD27+CD28+; Tem, CD45RA−CD27+/−CD28− and CD45RA−CD27−CD28− for CD8+ and CD4+, respectively; Ttd, CD45RA−CD27−CD28−. Individual and median values are shown. Two-sided p-values (Mann Whitney U test) are indicated.

Figure 4. Characterization of HIV cellular reservoir in meth users and control group. Total DNA and RNA were extracted from 5 × 10^6 frozen PBMCs and HIV DNA and RNA levels were quantified by ddPCR. For meth-users (orange squares, n = 16) and control group (blue circles, n = 34), levels of total HIV DNA and 2-LTRs were normalized per million CD4+ T cells (Panel A) and levels of unspliced (gag) and multiply spliced (tat-rev) HIV RNA were normalized per ng of RNA (Panel B). Individual and median values are shown. Two-sided p-values (Mann Whitney U test) are indicated.
subsets), increased CD4 and CD4 use, stratifying subjects based on the PI containing ART regiment (PI and non-PI use groups, n investigated if PI use was also associated with any of the parameters significantly associated with meth...n included a control group of HIV-infected individuals from the same cohort who did not use meth (UTox–, p = 0.03). In a multivariate analysis including meth use and PI use, meth use remained independently associated with CD8 T-cell proliferation and CD4 T-cell exhaustion (p < 0.05 in both cases), but not with proviral HIV DNA levels (p = 0.26).

Effects on recent meth-use. We identified 11 individuals out of 16 who self-reported meth use during the month immediately preceding sample collection. We performed a sensitivity analysis on this subset of individuals (n = 11) compared with non-meth users (n = 34). We were able to confirm our previous findings: increased levels of CD4 (in total and Tn subset) and CD8+ T-cell proliferation (total and all subsets), increased CD4+ T-cell activation (measured as the frequency of CD45RA–CD38+ T-cell proliferation and CD4 T-cell exhaustion (p < 0.05 in both cases), but not with proviral HIV DNA levels (p = 0.26).

Ex vivo results from the HIV Neurobehavioral Research Program (HNRP) samples. Acute effects of meth on lymphocyte function. Memory T-cell responses to mitogen (PHA) and opportunistic pathogen antigens were evaluated ex vivo using PBMC from HIV infected individuals (n = 19) with detectable meth in their urine (UTox+) at a scheduled clinic visit at the HNRP. Among these individuals, the median CD4+ T cell count was 438 [283–658] cells/μl and median log10 HIV RNA was 3.7 [3.1–4.5] copies/mL. We included a control group of HIV-infected individuals from the same cohort who did not use meth (UTox–, n = 18) but who were matched for HIV RNA levels (median log10 HIV RNA 3.0 IQR: 2.3–3.8 copies/mL) and CD4+ T-cell counts (median 402 IQR:217–618 cells/μl). Constitutive proliferation of T cells was significantly higher in UTox+ meth users than in UTox– participants (p = 0.045, Fig. 5A). However, UTox+ meth users demonstrated significantly reduced proliferative responses (i.e. lower stimulation index) after stimulation with PHA (p = 0.0005), CMV (p < 0.0001), Candida (p = 0.006), MTR protein (p = 0.01), Toxoplasma (p = 0.02) and supernatant of HIV infected cells (HIVAgSup) (p = 0.04, Fig. 5B) compared...
to UTox− subjects. Only a trend to lower proliferative response was observed for MTB (p = 0.06), and there was no significant difference between groups when the PBMCs were stimulated with chemically inactivated HIV MN and purified gag/p24/5.

Discussion
Previous studies of meth use by HIV-infected individuals have suggested that meth use is associated with faster disease progression, neurocognitive impairment, inflammation, and profound suppression of immune function12,25. Since meth use is also linked to reduced adherence to ART and a failure to suppress HIV replication, it has been difficult to differentiate between direct effects of meth and those resulting from residual HIV replication related to non-adherence12.

For the in vivo study, we included HIV-infected participants from the CCTG cohort who had HIV RNA levels suppressed in blood during long-term ART with the goal of isolating the effect of meth use on immune activation, T-cell proliferation and the HIV cellular reservoir. We found that these well-characterized meth users had significantly increased levels of CD4+ and CD8+ T-cell proliferation and increased activation (especially measured as the frequency CD45RA CD38+ ) and exhaustion of CD4+ T-cells. To further concentrate on the effects of meth use, we performed a sensitivity analysis on a subset of 11 individuals from the CCTG cohort who self-reported meth use during the month immediately preceding the collection of blood and semen. In this small sub-group, we also found increased levels of T-cell proliferation, activation and exhaustion. Taken together, these results suggest that meth use may have relatively long-term (>30 days) consequences with respect to immune function, but longitudinal studies will be necessary to confirm these findings.

Two non-mutually exclusive mechanisms could drive the increased frequencies of T-cell proliferation, activation and exhaustion observed in vivo: 1) a direct effect of meth on T cells and, 2) CMV-associated immune activation27, since meth users shed CMV in the genital tract more frequently than non-meth users. As we previously reported27, CMV-shedding increases the frequency of Ki67 cells in CD4+ T-cells, and to some extent, in CD8+ T-cell compartment. In this study, we found a general and non-specific increase of proliferation in all T-cell subsets, which suggests a direct effect of meth in these cells in vivo. However, we cannot rule out an additional effect of CMV-shedding on T-cell proliferation levels, especially in CD4+ T-cells27. Regarding immune activation, our results suggest that meth use and CMV-shedding increase the levels of activation markers independently and by different mechanisms. While CMV shedding is associated with increased levels of HLA-DR CD38+ in CD4+ T cells overall, meth use is linked to an increase in the frequency of memory CD45RA CD38+ CD4+ T cells. Therefore, both mechanisms might contribute and perhaps add to activation of the immune system, leading to an increased risk of morbidity and mortality28,38–40. Independent of the CMV-effects, more ex vivo studies will be required to determine the specific effects of meth on T-cell proliferation and activation.

Most of the meth users in our study were on PI-containing regimen, and higher levels of inflammation and immune activation are generally observed in subjects on PI-based regimens33,34. Although PI use has been associated with higher levels of CD8+ T-cell proliferation and CD4+ T-cell exhaustion, meth use still significantly contributed to the model after adjusting for PI use. It is possible that because meth-users have higher rates of Hepatitis C virus (HCV) co-infection, poor adherence to ART, and residual HIV load despite treatment, physicians may prefer PI-containing regimens, which have once daily dosing, high potency and a relatively high genetic barrier to resistance41.

Despite long term ART and fully suppressed HIV RNA in blood plasma, meth users tended to have higher levels of proviral HIV DNA in blood CD4+ cells and more frequent detection of HIV RNA in seminal plasma. However, the association of meth and higher proviral HIV DNA disappeared after adjusting for the presence of CMV shedding and PI use, suggesting that factors other than meth might play a larger role in the size and persistence of the HIV reservoir27. Alternatively, the meth-induced increased proliferation of CD4+ T cells could also contribute to an increased HIV DNA reservoir, due to a homeostatic proliferation of cells containing integrated HIV DNA32. Altogether, these findings could contribute to increased HIV transmission and worse HIV disease outcomes in subjects reporting meth use.

Further, to explore possible meth-related mechanisms of immune dysfunction, we performed ex vivo experiments using samples collected from UTox+ and UTox− HNRPs participants. Our data showed that, despite the increase of spontaneous T-cell proliferation in cells collected from UTox+ meth users, there was a clear concomitant loss of T-cell proliferative responses against various pathogens (i.e. CMV, HIV, Candida, MTB and Toxoplasma). This finding supports a hypothesis that meth use leads to poorer cytotoxic T lymphocyte (CTL)-mediated control of viral infections, like CMV and HIV, and may explain the higher rate of CMV and HIV shedding observed among meth users in the CCTG cohort. This observation was also corroborated in some animal studies, which have suggested that meth suppresses both innate and adaptive immunity42,43. For example, a similar effect of meth on lymphocyte function has been demonstrated in a mouse model that found the administration of meth accelerated the progression to death in mice infected with Histoplasma capsulatum, and this progression correlated with a decrease in the histoplasma-specific proliferative response3.

Several mechanisms could be involved in the reduction of specific proliferative responses. For instance, the treatment of murine cells with high doses of meth in vitro exerted direct immunosuppressive effect on dendritic cells and macrophages7. In these antigen presenting cells, meth inhibited antigen processing,
presentation, and phagocytosis by collapsing the pH gradient across acidic organelles. Another interesting mechanistic pathway of immune dysfunction may be oxidative damage to mitochondria by meth, which has been demonstrated in vitro, leading to impairment of lymphocyte function. Interestingly, antioxidants could attenuate the mitochondrial damage in this model, suggesting that increased levels of reactive species from meth could be the cause of the diminished proliferative capacity of lymphocytes. Further studies need to be performed in humans to characterize specific meth-related deficits in lymphocyte and monocyte/macrophage functions.

In summary, these studies demonstrate that the interplay between meth, CMV and HIV is complex. In particular, meth use in HIV-infected individuals may contribute to activation and exhaustion of the immune system, especially the CD4+ T-cell compartment, even when these individuals have HIV replication suppressed in blood plasma. Such ongoing proliferation exhausts immune cells, potentially preventing antigen specific T-cell proliferation and reducing cytotoxic T lymphocyte activity and antibody production. The consequence result could be failure to control reactivating endogenous pathogens, such as CMV (which is consistent with the increased shedding of CMV in the genital tract observed in the present study), and this persistent viral replication might further affect and exhaust the immune system, which in turn could diminish capacity to control virus replication (Fig. 6). The long-term clinical impact of this circular interaction likely explains in part why meth users have worse HIV disease outcomes despite use of effective ART.

Material and Methods

Ethics Statement. Ethical approval for this study (ClinicalTrials.gov Identifier: NCT01198418, grant title: A Web-based Intervention Study to Reduce High-risk Sexual Behavior by Persons Living With HIV/AIDS [PLWH]) was obtained from the Offices of Human Research Protections Program of: the University of California San Diego, the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, and the University of Southern California in compliance with the Declaration of Helsinki. All determinations were performed with fully informed written consent from all participants involved in this study. All experiments were performed in accordance with approved guidelines and regulations.

Participants, samples and clinical laboratory tests. Two distinct clinical cohorts were included in the described analysis for the in vivo (California Collaborative Treatment Group [CCTG] cohort) and ex vivo (HIV Neurobehavioral Research Program [HNR]P cohort) experimental part.

CCTG Cohort. The CCTG-592 trial is a prospective study of an internet-based behavioral intervention among MSM with ongoing transmission risk behaviors to reduce sexually transmitted infections. This study included baseline collection of paired blood and semen samples in a total of 179 HIV-infected
MSM who were on or off ART44. For this cross-sectional study, we included baseline samples from a subset of 50 subjects selected sequentially from among those virologically suppressed on ART (plasma HIV RNA levels <50 copies/ml) on their last clinical visit (within 3 months prior to the collection of seminal and blood samples), and who had viable frozen PBMC aliquots available. Use of ART, meth and other drugs (marijuana, cocaine, heroin, alcohol and other “club” drugs, including Ecstasy, γ-hydroxybutyric acid [GHB], amyl nitrates, ketamine) were assessed monthly with a self-administered internet-based survey along with other risk behaviors for the 12 months of study follow-up. Since meth is highly addictive and recurrent use is common, meth use (or other drug-use) was defined as any reported consumption at least one survey over the period of the study. All included participants were cytomegalovirus (CMV) seropositive45. Semen was collected and processed as previously described46,47. Blood absolute CD4+ T-lymphocyte counts were measured by flow cytometry, and HIV RNA levels in blood plasma were quantified by the Amplicor HIV Monitor Test (limit of detection 50 copies/mL, Roche Molecular Systems Inc).

**HNRNP cohort.** Ex-vivo T-cell proliferation results were derived from 37 HIV-infected subjects enrolled in studies at the HRNP. Fresh peripheral blood mononuclear cells (PBMCs) were harvested for ex vivo anti-HNRP cohort. Ex-vivo Systems Inc). were quantified by the Amplicor HIV Monitor Test (limit of detection 50 copies/mL, Roche Molecular

**In vivo experiments performed on CCTG samples.** Multiparameter Flow Cytometry Analysis. Immune activation, proliferation and exhaustion were assessed using frozen PBMCs from the CCTG592 cohort. Aliquots of 5 million PBMCs were quickly thawed at 37 °C, resuspended in RPMI supplemented with 20% FBS, incubated at room temperature for 20 minutes to allow cell recovery before staining. Cell viability was assessed using the LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit (Life Technologies). Four subjects were excluded because their samples demonstrated <85% cell viability. Approximately 300,000–500,000 PBMC per tube were stained for cell surface markers prior to fixation, and when required, followed with permeabilization for intracellular protein detection (FOXp3/transcription factor Staining Buffer set, ebioscience). The stained cells were acquired on a FACS Canto (BD Biosciences). We used the following antibody combinations: (tube 1) HLA-DR–FITC (Clone G46-6), CD45RA–PE (Clone HI100), CD4–PerCP-Cy5.5 (Clone SK3), CD38–PE-Cy7 (Clone HB7), CD27–APC (Clone L128), CD3–APC-Cy7 (Clone SK7), CD8–V450 (Clone RPA-T8); (tube 2) Ki67–FITC (Clone B56), CD45RA–PE (Clone HI100), CD4–PerCP-Cy5.5 (Clone SK3), CCR7–PE-Cy7 (Clone 3D12), CD27–APC (Clone L128), CD3–APC-Cy7 (Clone SK7) and CD8–V450 (Clone RPA-T8); (tube 3) CCR5–FITC (Clone 2D7/CCR5), CD45RA–PE (Clone HI100), CD14–ECBD (Clone RM052), CD4–PerCP-Cy5.5 (Clone SK3), CCR7–PE–Cy7 (3D12), CD27–APC (Clone L128), CD3–APC-Cy7 (Clone SK3) and CD8–V450 (Clone RPA-T8); and (tube 4) CD57–FITC (Clone NK-1), CD45RA–PE (Clone HI100), CD28–ECBD (Clone CD28.2), CD4–PerCP-Cy5.5 (Clone SK3), PD-1–PE-Cy7 (Clone EH12), CD27–APC (Clone L128), CD3–APC-Cy7 (Clone SK7), CD8–V450 (Clone RPA-T8). (All antibodies were from BD Biosciences, except CD14-ECBD and CD28-ECBD, which were from Beckman Coulter). The antibody combinations in Tube 1 were used to assess naïve (Tn, CD45RA+CD27+), central memory (Tcm, CD45RA-CD27+), effector memory (Tem, CD45RA-CD27+) and terminally differentiated (Tde, CD45RA-CD27+) CD4+ and CD8 T-cell subsets. With Tube 2 and 3, T-cell subsets were defined as: Tn, CD45RA+CD27+CCL7+; Tcm, CD45RA-CD27+CCL7+; Tem, CD45RA-CD27+CCL7+; and Tde, CD45RA+CD27+CCL7+ in both the CD4+ and CD8+ subsets. T-cell subsets in tube 4 were defined as: Tn, CD45RA+CD27+CD28+; Tcm, CD45RA-CD27+CD28+; Tem, CD45RA+CD27+CD28+ and CD45RA+CD27+CD28+ for CD8+ and CD4+, respectively; Tde, CD45RA-CD27+CD28+. Immune activation was defined by CD38+HLA-DR+ or the expression of CD38 or HLA-DR in memory subsets. Proliferation and exhaustion was defined by expression of Ki67+ or PD-1+ respectively, in total CD4+ and CD8+ T-cell populations and subsets. Analyses of flow cytometry data were performed using Flow Jo software (version 9.6.2).

**Soluble markers.** Soluble CD14 (sCD14) and CD163 (sCD163) were quantified in plasma by ELISA (R&D systems and Thrillium, respectively), and interpreted as surrogate markers of monocyte activation.

**Quantification of total and 2-Long Terminal Repeat (2-LTR) HIV DNA, and Herpesvirus DNA in PBMC and Semen.** DNA was extracted from 5 million PBMC and 200μl seminal plasma for each participant (QIAamp DNA Mini Kit, Qiagen, CA). For PBMC, total HIV DNA (pol) and 2-LTR circles were quantified by droplet digital PCR (ddPCR) from extracted DNA48, as described previously47. Copy numbers were calculated as the mean of replicate PCR measurements and normalized to one million CD4+ T cells as determined by RPP30 (total cell count) and flow cytometry (percentage of CD4+ T cells within total PBMCs). Levels of CMV and Epstein-Barr virus (EBV), were also measured by real-time PCR in the DNA extracted from seminal plasma, as described previously46.
Quantification of cellular HIV RNA in PBMC. Cellular HIV RNA (unspliced [gag] and multiply spliced [encoding for tat-rev]) was measured for the subset of 42 cohort participants with enough available PBMC to perform these analyses, as described previously27. Copy numbers were calculated as the mean of replicate PCR measurements, and normalized to total RNA as determined by A260/A280 absorbivity ratio using a NanoDrop 2000 spectrophotometer (Thermo Scientific).

Ex vivo experiments performed on HNRPs. Ex vivo T-cell proliferative responses to antigen stimuli. Fresh PBMCs from HIV-infected individuals were cultured with antigen or mitogen in triplicate in Iscoves media supplemented with 5% human AB serum for 7 days at 37°C in 5% CO2 in presence of phytohemagglutinin (PHA) or pathogen antigens: heat-inactivated CMV AD-169 (grown by Dr. Rachel Schrier’s lab), Candida (Greer Biologics), Mycobacterium tuberculosis (MTB) protein (supplied by Dr. Henry Boom), Toxoplasma [Toxo] (donated by Dr. Sharon Reed), HIV gag/p24/p5 [Protein Sciences] and heat-inactivated (1 hour, 56°C) supernatant of HIV infected T cells [HIVAgsuppt], grown by Dr. Rachel Schrier’s lab). Chemically inactivated HIV MN was supplied by Dr. Jeffrey Lifson at NCI. PBMC cultured only with medium were used as unstimulated control. Cells were pulsed with [3H]-thymidine (0.5 ACi/well, NEN) 24 hours before harvest. Radioactivity was determined with a liquid scintillation counter (Packard Top Count). Data were presented as counts per minute (cpm) and triplicates were averaged. Stimulation index (SI) was calculated as the ratio of the mean cpm as measured for each stimulus (PHA and other antigens) to the mean cpm of unstimulated control.

Statistics. Statistical analyses were performed using GraphPad Prism (version 6) and R statistical software. HIV RNA, CMV DNA, and EBV DNA levels were transformed to log10 values, and CMV genital shedding and presence of LTR were dichotomized (undetectable/detectable). Comparisons were made between the meth users and non-meth users using Fisher exact test (for dichotomous data) or Mann Whitney U test (for continuous data). To explore the confounding effects in proliferation, immune exhaustion and HIV reservoir size, we adjusted our analysis for CMV-shedding in the genital tract and use of a protease inhibitor (PI) in the ART regimen using a multivariate fixed-effects regression model when one or both of these potential confounders had a p-value ≤ 0.1 in univariate analyses. Continuous variables were assessed for normality by the Shapiro-Wilk test and log-transformed if necessary.

References
1. Durell, T. M., Kroutil, L. A., Crits-Christoph, P., Barcha, N. & Van Brunt, D. L. Prevalence of nonmedical methamphetamine use in the United States. Subst Abuse Treat Prev Policy 3, 19 (2008).
2. Maxwell, J. C. & Ratkowski, B. A. The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992-2007. Drug Alcohol Rev 27, 229–235 (2008).
3. Gonzales, R., Moorey, L. & Rawson, R. A. The methamphetamine problem in the United States. Annu Rev Public Health 31, 385–398 (2010).
4. Colfax, G. & Shoptaw, S. The methamphetamine epidemic: implications for HIV prevention and treatment. Curr HIV/AIDS Rep 2, 194–195 (2005).
5. Harris, D. S. et al. The bioavailability of intranasal and smoked methamphetamine. Clin Pharmacol Ther 74, 475–486 (2003).
6. Cho, A. K., Melega, W. P., Kuczynski, R. & Segal, D. S. Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse 39, 161–166 (2001).
7. Talley, Z., et al. Methamphetamine Inhibits Antigen Processing, Presentation, and Phagocytosis. Plas Pathog 4, e28 (2008).
8. Martinez, L. R., Mihu, M. R., Gácser, A., Santambrogio, L. & Nosanchuk, J. D. Methamphetamine enhances histoplasmosis by immunosuppression of the host. J Infect Dis 200, 131–141 (2009).
9. Potula, R. et al. Methamphetamine causes mitochondrial oxidative damage in human T lymphocytes leading to functional impairment. The Journal of Immunology 185, 2867–2876 (2010).
10. Colfax, G. N. et al. Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance. AIDS 21, 239–241 (2007).
11. Fairbairn, N. et al. Crystal methamphetamine injection predicts slower HIV RNA suppression among injection drug users. Addict Behav 36, 762–763 (2011).
12. Ellis, R. J. et al. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis 188, 1820–1826 (2003).
13. Carrico, A. W., Johnson, M. O., Colfax, G. N. & Moskowitz, J. T. Affective correlates of stimulant use and adherence to antiretroviral therapy among HIV-positive methamphetamine users. AIDS Behav 14, 769–777 (2010).
14. Kapadia, F. et al. The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use. Addiction 100, 990–1002 (2005).
15. Shoptaw, S. & Reback, C. J. Methamphetamine use and infectious disease-related behaviors in men who have sex with men: implications for interventions. Addiction 102 Suppl 1, 130–135 (2007).
16. Prid, D. et al. Methamphetamine enhances Cryptococcus neoformans pulmonary infection and dissemination to the brain. MBio 4, (2013), doi: 10.1128/mBio00400–13.
17. Stahlman, S., Javanbakht, M., Stirland, A., Guerry, S. & Gorbach, P. M. Methamphetamine Use Among Women Attending Sexually Transmitted Disease Clinics in Los Angeles County. Sexually Transmitted Diseases 40, 632–638 (2013).
18. Gonzales, R., Marinelli-Casey, P., Shoptaw, S., Ang, A. & Rawson, R. A. Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment. Journal of Substance Abuse Treatment 31, 195–202 (2006).
19. Moltz, E., Truxx, S. R., Ruts, J. D. & Sun, R. K. Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. West. J. Med. 168, 93–97 (1998).
20. Mimiaga, M. J. et al. Experiences and sexual behaviors of HIV-infected MSM who acquired HIV in the context of crystal methamphetamine use. AIDS Educ Prev 20, 30–41 (2008).
21. Nair, M. P. N. et al. Methamphetamine enhances HIV-1 infectivity in monocyte derived dendritic cells. J Neuroimmune Pharmacol 4, 129–139 (2009).
22. Nair, M. P. N. & Saiyed, Z. M. Effect of methamphetamine on expression of HIV coreceptors and CC-chemokines by dendritic cells. Life Sci 88, 987–994 (2011).
23. Potula, R. & Persidsky, Y. Adding fuel to the fire: methamphetamine enhances HIV infection. Am J Pathol 172, 1467–1470 (2008).

24. Toussi, S. S. et al. Short communication: Methamphetamine treatment increases in vitro and in vivo HIV replication. AIDS Res Hum Retroviruses 25, 1117–1121 (2009).

25. Okoye, A. et al. Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med 204, 2171–2185 (2007).

26. Clase, P. J. The molecular basis of HIV entry. Cell. Microbiol. 14, 1183–1192 (2012).

27. Gianella, S. et al. Cytomegalovirus Replication in Semen Is Associated with Higher Levels of Proviral HIV DNA and CD4+ T Cell Activation during Antiretroviral Treatment. Journal of virology 88, 7818–7827 (2014).

28. Boiffil, M. et al. Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS (London, England) 10, 827–834 (1996).

29. Giorgi, J. V. et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 179, 859–870 (1999).

30. Massanella, M. et al. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS (London, England) 24, 959–968 (2010).

31. Gianella, S. et al. Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatment. Journal of virology 88, 7818–7827 (2014).

32. Chomont, N. et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nature Medicine 15, 893–900 (2009).

33. Madden, E. et al. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS (London, England) 22, 707–715 (2008).

34. Cassol, E. et al. Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis 13, 203 (2013).

35. Buzon, M. J. et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 16, 460–465 (2010).

36. Hatano, H. et al. Increase in 2-Long Terminal Repeat Circles and Decrease in D-dimer After Raltegravir Intensification in Patients With Treated HIV Infection: A Randomized, Placebo-Controlled Trial. J Infect Dis 208, 1436–1442 (2013).

37. Rippeth, J. D. et al. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc 10, 1–14 (2004).

38. Giorgi, J. V. et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 29, 346–355 (2002).

39. Hunt, P. W. et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 17, 1907–1915 (2003).

40. Hunt, P. W. et al. Impact of CD4+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS (London, England) 25, 2123–2131 (2011).

41. Wensing, A. M. J., Van Maarseveen, N. M. & Nijhuis, M. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. Antiviral Res 85, 59–74 (2010).

42. Yu, Q. et al. Chronic methamphetamine exposure alters immune function in normal and retrovirus-infected mice. Int. Immunopharmacol. 2, 951–962 (2002).

43. In, S.-W., Son, E.-W., Rhee, D.-K. & Pyo, S. Methamphetamine Administration Produces Immunomodulation in Mice. Journal of Toxicology and Environmental Health, Part A 68, 2135–2145 (2005).

44. Gianella, S. et al. Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men. Clin Infect Dis 57, 441–447 (2013).

45. Gianella, S. et al. Virologic Correlates of Anti-CMV IgG Levels in HIV-1-Infected Men. J Infect Dis (2013). doi: 10.1093/infdis/jit434.

46. Gianella, S. et al. Associations between Virologic and Immunologic Dynamics in Blood and in the Male Genital Tract. Journal of virology 86, 1307–1315 (2012).

47. Butler, D. M. et al. The origins of sexually transmitted HIV among men who have sex with men. Sci Transl Med 2, 18re1 (2010).

48. Strain, M. C. et al. Highly Precise Measurement of HIV DNA by Droplet Digital PCR. Plos One 8, e59943 (2013).

Acknowledgments

We are grateful to the participants in the California Collaborative Treatment Group (CCTG) and the HIV Neurobehavioral Research Center (HNRC). We would like to acknowledge the investigators and team members in the CCTG, UCSD HNRC, the UCSD Translational Methamphetamine AIDS Research Center (TMARC), and the CFAR Genomic, Translational Virology and Flow Cytometry Cores. We would like to acknowledge all the nurses at all the enrollment sites, and Christy Anderson for her very helpful discussion. HIV RNA quantification standard was obtained through the NIH AIDS Research and Reference Reagent Program, DAIDS, NIAID: HIV VQA RNA Quantification Standard from the DAIDS Virology Quality Assurance Program. Primer and Probe for quantification of herpesviruses as well as the plasmids and quantification standards were kindly provided by Fred Lakeman. MM and MFO were supported by EMBO and CNPq-Brazil post-doctoral fellowships, respectively. Financial Disclosure add all grant number: This work was supported by the Department of Veterans Affairs, the James Pendleton Charitable Trust; amfAR grant 108537 with support from FAIR, the US National Institutes of Health (NIH) awards, AI69432, AI1106039, MH62512, MH083552, AI1100665, AI077304, AI047745, AI174621, GM093939AI080353, AI096113 (CARE Collaboratory), AI306221 (CFAR), AI27670 (ACTU), and AI064086 (K24 to RHH), AI14368, MH100979; the California HIV/AIDS Research Program RN07-SD-702, MC08-SD-00 and EI-11-SD-005; the National Center for Advancing Translational Sciences through UCLA CTSI Grant UL1TR000124 and the National Institute of General Medical Sciences grant GM093939; TMARC developmental grant (P50DA026306 and R25MH081482). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Contributions
Conceived and designed the experiments: M.M., S.G., R.S., D.M.S. and S.H.M. Performed the experiments: M.M., S.G., R.S., J.D. and M.F.O. Analyzed the data: M.M., S.G., J.D., R.S., J.P.S., D.M.S. and S.R.M. Enrolled participants: E.S.D., M.P.D., C.B. and R.H.H. Wrote and revised the manuscript: M.M., S.G., D.D.R., R.H.H., E.S.D., M.P.D., S.J.L., D.M.S. and S.R.M.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: MM, SG, RS, JD, JPS, MFO and CB do not have any commercial or other associations that might pose a conflict of interest. For the rest of authors, there is potential Competing Interest. DDR has served as a consultant for Bristol-Myers Squibb, Gilead Sciences, Merck & Co, Monogram Biosciences, and Chimerix. SJL has received grant support from Gilead Sciences. ESD has received grant support from Bristol Myers Squibb, Gilead, and ViiV and has acted as a consultant for Abbvie, Bristol Myers Squibb, Gilead, Merck, Teva and ViiV. MPD has received grant support from Merck, Gilead, Serono, and ViiV and has served as a consultant to Serono. RHH reports having received honoraria or consultant fees from BMS, Gilead Sciences and Janssen and research support (to UCSD) from Abbott, GlaxoSmithKline, Pfizer, and Merck. DMS has received grant support from ViiV Pharmaceuticals and consultant fees from Gen-Probe and Testing Talent Services. SRM has served on advisory boards for and received grant support from Gilead Sciences.

How to cite this article: Massanella, M. et al. Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy. Sci. Rep. 5, 13179; doi: 10.1038/srep13179 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/